Throughout the world, 10 million breast cancer survivors have a lifetime risk for developing lymphedema, a chronic condition that involves swelling of the limbs and impacts physical and psychosocial health. Second only to the recurrence of cancer, it is the most dreaded effect of breast cancer treat

In a new study led by the University of Michigan Health System, women more than doubled their fruit and vegetable intakes and dramatically increased their consumption of "good" fats when they were counseled by registered dietitians and provided with a list of guidelines on the amount of certain food

The first British baby girl free of the faulty BRCA 1 gene, which significantly raises a woman's chances of developing breast cancer, is due to be born soon. The girl has been genetically selected to be free of the faulty gene. As an embryo, she was screened to make sure she did not have the faulty

Two separate meta-analyses of clinical trials from around the world that tested tamoxifen against aromatase inhibitor drugs in postmenopausal women with early breast cancer have each reached the same conclusion: aromatase inhibitors are more effective in preventing breast cancer from coming back. Pa

MedWire News: The findings of a systematic review show that nonhormonal treatment regimens including anthracycline-based regimens and taxanes, have improved overall survival in women with metastatic or recurrent inoperable breast cancer over the last 35 years. Previous studies have tested numerous

MedWire News: Naturally occurring phenolic compounds found in extra-virgin olive oil appear to counter the oncogenic effects of human epidermal growth factor receptor (HER)-2 in breast cancer cells grown in vitro, study results show. The findings may partly explain why previous studies have shown t

Without HER2-targeted therapy, HER2-positive breast cancer has a higher risk of recurrence than HER2-negative breast cancer, even when the breast cancer is small (1 cm or less); this raises the possibility that even women with very small HER2-positive breast cancers may benefit from a HER2-targeted

According to the results of a Phase III clinical trial, the experimental drug denosumab significantly improves bone density among women with non-metastatic breast cancer treated with an aromatase inhibitor. These results were published in the Journal of Clinical Oncology.  Each year more than

Standard one year Herceptin treatment provides long-term benefit to patients with high risk of recurrence About 70% of women with locally advanced HER2-positive breast cancer were free of their disease three years after initiation of therapy when treated with Herceptin plus chemotherapy before surg

New data released demonstrate that the addition of Zometa(R) (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than chemotherapy alone in women with early-stage disease. These neo-adjuvant subset results from the ret